Get the Weekly Intelligence Brief — top committee picks every Sunday.

HSIC vs IONS

Henry Schein vs Ionis Pharmaceuticals, Inc. — AI-powered side-by-side comparison
HSIC
Henry Schein
67
Buy
VS
IONS
Ionis Pharmaceuticals, Inc.
43
Reduce
MetricHSICIONS
AI Score 67 43
Price $89.16 $55.38
P/E Ratio 25.77× -16.02×
ROE 12.3% -77.9%
Revenue Growth YoY
Gross Margin 30.3% 98.2%
Debt / Equity 1.21× 5.50×
Dividend Yield 0.0% 0.0%
RSI (14) 59.4 46.6
Beta 0.808 0.4
Expected Upside +0.8%

AI Committee View

Current Innellis committee reasoning for HSIC versus IONS.
HSIC leads by 24 points.

HSIC scores 67/100 (Buy) versus IONS at 43/100 (Reduce).

HSIC Committee View
75% agreement
4 analysts

The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.

Bull Case
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
IONS Committee View
50% agreement
6 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -7.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • MACD histogram positive -- bullish momentum — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • Price-to-book of 26.2x prices in significant intangible value — Value
  • ROE of only -110.9% -- cheap may mean cheap for a reason — Value
  • Debt-to-equity of 4.77 adds balance-sheet risk to the value case — Value
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
HSIC Full Analysis IONS Full Analysis